The document summarizes information from the US VBA Tracker, which tracks value and outcomes-based innovative contracting in the US. It provides data on the number and types of outcomes-based contracts from 2014-2018. Key findings include CMS striking deals for Luxturna and Kymriah in 2018, and Express Scripts introducing drug leasing. Harvard Pilgrim remains the top payer undertaking such contracts, while Amgen is the most prolific manufacturer. The majority of contracts aim to manage drug affordability in competitive markets.